Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Defining 'Substantial Efficacy': Post Hoc Analysis OK (When US FDA Does It)

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration's approach to weighing "non-positive" efficacy data against the results from two successful clinical trials for an antidepressant drew protests from some members of its Psychopharmacologic Drugs Advisory Committee on Dec. 1. The development could have implications beyond antidepressant drug development and highlights the potential need for FDA guidance on this issue.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel